Data / Form D filings / Cerecin Inc.
Cerecin Inc.: Form D filings
Cerecin Inc., a biotechnology company in Denver, CO, filed 15 Form D notices with the SEC between 2009 and 2024. The latest, on June 25, 2024, reports $3.7 million sold of a $7 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 44 COOK STREET, SUITE 100-71, Denver, CO, 80206
- Phone
- (303) 999-3700
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1293610
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024 | New notice | $7,000,000 | $3,740,000 | $3,260,000 | 10 | Jun 10, 2024 | sec.gov |
| Aug 18, 2022 | New notice | $39,999,999 | $7,220,002 | $32,779,997 | 1 | Aug 3, 2022 | sec.gov |
| Sep 29, 2021 | New notice | $30,000,000 | $10,000,001 | $19,999,999 | 3 | Sep 14, 2021 | sec.gov |
| Feb 5, 2021 | New notice | $14,999,935 | $10,000,000 | $4,999,935 | 1 | Jan 21, 2021 | sec.gov |
| Mar 26, 2018 | New notice | $50,139,527 | $17,639,537 | $32,499,990 | 2 | Feb 9, 2018 | sec.gov |
| Jan 21, 2014 | Amendment | $84,081,610 | $84,081,610 | 2 | Jul 17, 2012 | sec.gov | |
| Oct 25, 2013 | Amendment | $79,081,610 | $79,081,610 | 2 | Jul 17, 2012 | sec.gov | |
| May 7, 2013 | Amendment | $69,081,610 | $69,081,610 | 2 | Jul 17, 2012 | sec.gov | |
| Oct 12, 2012 | Amendment | $34,081,610 | $34,081,610 | 2 | Jul 17, 2012 | sec.gov | |
| Jul 27, 2012 | New notice | $18,397,296 | $18,397,296 | 2 | Jul 17, 2012 | sec.gov | |
| May 24, 2012 | New notice | $4,882,125 | $4,882,125 | 1 | Apr 18, 2012 | sec.gov | |
| May 24, 2012 | New notice | $3,900,787 | $3,900,787 | 1 | Oct 10, 2011 | sec.gov | |
| Dec 21, 2010 | New notice | $11,000,000 | $11,000,000 | 3 | Dec 7, 2010 | sec.gov | |
| Mar 15, 2010 | New notice | $9,487,313 | $9,487,313 | 4 | Mar 2, 2010 | sec.gov | |
| Apr 23, 2009 | Amendment | $35,170,200 | $26,051,995 | $9,118,205 | 4 | Nov 19, 2008 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jerris T. Knaisch | Executive Officer | |
| Claude T. Nash | Director | |
| Rahul T. Rajashekar | Director | |
| Dilpreet T. Singh | Executive Officer | |
| KiKab T. Kim | Director | |
| Nicholas Charles Stacey | Executive Officer, Director | |
| Hans-Juergen T. Woerle | Director | |
| Samuel T. Henderson | Executive Officer | |
| Wolfgang T. Reichenberger | Director |
Other biotechnology companies in Colorado that filed recently
- GelSana Therapeutics, Inc. $4.4 million · Oct 8, 2026
- Renovare Therapeutics, Inc. $100,000 · Oct 2, 2026
- EnteroTrack, LLC $2 million · Sep 25, 2026
- Shiverbright Technologies, Inc. $200,000 · Aug 7, 2026
Every Form D from the week of Jun 24, 2024 · All recent filings in Colorado · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cerecin Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.